DK2747776T3 - : RELATIONSHIPS TO USE IN INCREASING COAGULATION - Google Patents

: RELATIONSHIPS TO USE IN INCREASING COAGULATION Download PDF

Info

Publication number
DK2747776T3
DK2747776T3 DK12758914.1T DK12758914T DK2747776T3 DK 2747776 T3 DK2747776 T3 DK 2747776T3 DK 12758914 T DK12758914 T DK 12758914T DK 2747776 T3 DK2747776 T3 DK 2747776T3
Authority
DK
Denmark
Prior art keywords
inhibitor
bleeding
plasma
thrombin
rsl
Prior art date
Application number
DK12758914.1T
Other languages
Danish (da)
English (en)
Inventor
Cornelis Erik Hack
Cafer Yildiz
Original Assignee
Umc Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umc Utrecht Holding Bv filed Critical Umc Utrecht Holding Bv
Application granted granted Critical
Publication of DK2747776T3 publication Critical patent/DK2747776T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
DK12758914.1T 2011-08-25 2012-08-24 : RELATIONSHIPS TO USE IN INCREASING COAGULATION DK2747776T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527140P 2011-08-25 2011-08-25
PCT/NL2012/050581 WO2013028070A2 (en) 2011-08-25 2012-08-24 Compounds for use in boosting coagulation

Publications (1)

Publication Number Publication Date
DK2747776T3 true DK2747776T3 (en) 2018-09-17

Family

ID=46845975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12758914.1T DK2747776T3 (en) 2011-08-25 2012-08-24 : RELATIONSHIPS TO USE IN INCREASING COAGULATION

Country Status (14)

Country Link
US (1) US20140356377A1 (cg-RX-API-DMAC10.html)
EP (1) EP2747776B1 (cg-RX-API-DMAC10.html)
JP (2) JP6198277B2 (cg-RX-API-DMAC10.html)
CN (1) CN103930129A (cg-RX-API-DMAC10.html)
AU (1) AU2012299524B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014004297B1 (cg-RX-API-DMAC10.html)
CA (1) CA2846494C (cg-RX-API-DMAC10.html)
CY (1) CY1120688T1 (cg-RX-API-DMAC10.html)
DK (1) DK2747776T3 (cg-RX-API-DMAC10.html)
ES (1) ES2689776T3 (cg-RX-API-DMAC10.html)
HU (1) HUE039590T2 (cg-RX-API-DMAC10.html)
PL (1) PL2747776T3 (cg-RX-API-DMAC10.html)
PT (1) PT2747776T (cg-RX-API-DMAC10.html)
WO (1) WO2013028070A2 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150127202A (ko) 2013-03-14 2015-11-16 바이엘 헬스케어 엘엘씨 헤파린과 복합체화된 항트롬빈 베타에 대한 모노클로날 항체
EP3904519A1 (en) 2014-10-30 2021-11-03 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
WO2017158176A1 (en) * 2016-03-18 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
TWI772724B (zh) 2018-12-21 2022-08-01 英商克馬伯有限公司 具有共同輕鏈的FIXaxFX雙專一性抗體
JP6883899B1 (ja) * 2020-12-07 2021-06-09 株式会社血栓トランスレーショナルリサーチラボ 血液凝固検査試薬、および血液凝固検査方法
PL440675A1 (pl) * 2022-03-17 2023-09-18 Politechnika Wrocławska Związki do równoległego wykrywania i hamowania proteaz szlaku krzepnięcia - APC, trombiny, czynnika Xa i czynnika XIa w ludzkim osoczu

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748913A (en) * 1904-01-05 Fo model
WO2009013251A1 (en) * 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
DE102011081871A1 (de) * 2011-08-31 2013-02-28 Henkel Ag & Co. Kgaa Oxazolidine zur Fehlgeruchsbekämpfung

Also Published As

Publication number Publication date
US20140356377A1 (en) 2014-12-04
CA2846494C (en) 2020-10-20
WO2013028070A2 (en) 2013-02-28
AU2012299524B2 (en) 2017-03-23
EP2747776B1 (en) 2018-07-11
BR112014004297A2 (pt) 2017-03-28
JP2017186340A (ja) 2017-10-12
ES2689776T3 (es) 2018-11-15
CA2846494A1 (en) 2013-02-28
PT2747776T (pt) 2018-10-31
AU2012299524A1 (en) 2014-03-13
JP6198277B2 (ja) 2017-09-20
PL2747776T3 (pl) 2019-03-29
CN103930129A (zh) 2014-07-16
BR112014004297B1 (pt) 2021-12-14
WO2013028070A3 (en) 2013-04-18
HUE039590T2 (hu) 2019-01-28
JP2014529606A (ja) 2014-11-13
EP2747776A2 (en) 2014-07-02
CY1120688T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
AU2012299524B2 (en) Compounds for use in boosting coagulation
US20050181978A1 (en) Therapeutic use of factor XI
JP2014508159A (ja) インヒビターを保有するまたは保有しない血友病aまたはbを治療するためのglaドメイン欠失因子xa
JP2013531651A (ja) 線溶亢進を伴う凝固障害の処置
Thomassen et al. Tissue factor‐independent inhibition of thrombin generation by tissue factor pathway inhibitor‐α
ES2119165T5 (es) Nueva actividad de cofactor anticoagulante.
EP0500800A1 (en) Antihemostatic factor vii peptides.
CN115835880A (zh) Adamts13蛋白质变体及其用途
WO2005049070A1 (en) Therapeutic use of factor xi
JP2022513332A (ja) プロテインsレベルの決定方法
US5187155A (en) Anticoagulant peptides
US20140256640A1 (en) Treatment of coagulopathy with hyperfibrinolysis
KR20020042618A (ko) 촉매성 ⅷ 안티팩터의 동종항체
US20030143759A1 (en) Assays for determining anticoagulant cofactor activity
WO2007014772A2 (en) Direct and indirect effector cell protease receptor-1 (epr-1) inhibitors as antiplatelet agents
JP2019516347A (ja) 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド
Turecek et al. Factor eight inhibitor bypassing activity
Lindo Jr Characterization of an alpha2-antiplasmin antibody
WO2010078469A2 (en) Sand fly salivary proteins as novel factor xa inhibitors and methods of use
CA2488968A1 (en) Peptides for regulation of urokinase (upa) and tissue type (tpa) plasminogen activator and method of optimizing therapeutic efficacy
US20150005238A1 (en) Treatment of coagulopathy with hyperfibrinolysis
WO2017064213A1 (en) Method and compounds for treatment and prophylaxis of bleeding episodes
US20070031412A1 (en) Direct and indirect effector cell protease receptor-1 (EPR-1) Inhibitors as antiplatelet agents
McAiney Characterization of the I4399M Variant of Apolipoprotein (a): Implications for Altered Prothrombotic Properties of Lipoprotein (a)